Compare ACADIA Pharmaceuticals Inc. (ACAD) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs SAP SE — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while SAP SE trades at $207.06 (market cap $240.81B). The key difference: SAP SE is far larger — about 47.5× ACADIA Pharmaceuticals Inc.'s market cap, and SAP SE pays a 1.4% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SAP | |
|---|---|---|
Market Cap | $5.07B | $240.81B |
Sector | Health | Technology |
52-Week High | $29.41 | $280.46 |
52-Week Low | $20.06 | $146.38 |
Enterprise Value | $4.19B | $239.52B |
Dividend Yield | — | 1.4% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
